66 related articles for article (PubMed ID: 34847622)
21. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era.
Lyon TD; Thompson RH; Shah PH; Lohse CM; Boorjian SA; Costello BA; Cheville JC; Leibovich BC
J Urol; 2020 Feb; 203(2):275-282. PubMed ID: 31393812
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
23. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of Renal Cell Carcinoma.
Capitanio U; Bensalah K; Bex A; Boorjian SA; Bray F; Coleman J; Gore JL; Sun M; Wood C; Russo P
Eur Urol; 2019 Jan; 75(1):74-84. PubMed ID: 30243799
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
[TBL] [Abstract][Full Text] [Related]
26. Role of metastasis-directed treatment in kidney cancer.
Psutka SP; Master VA
Cancer; 2018 Sep; 124(18):3641-3655. PubMed ID: 29689599
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
28. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Zaid HB; Parker WP; Safdar NS; Gershman B; Erwin PJ; Murad MH; Boorjian SA; Costello BA; Thompson RH; Leibovich BC
J Urol; 2017 Jan; 197(1):44-49. PubMed ID: 27473875
[TBL] [Abstract][Full Text] [Related]
29. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Cubilla AL; Humphrey PA; Reuter VE; Ulbright TM
Eur Urol; 2016 Jul; 70(1):93-105. PubMed ID: 26935559
[TBL] [Abstract][Full Text] [Related]
30. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
[TBL] [Abstract][Full Text] [Related]
31. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
[TBL] [Abstract][Full Text] [Related]
32. International variations and trends in renal cell carcinoma incidence and mortality.
Znaor A; Lortet-Tieulent J; Laversanne M; Jemal A; Bray F
Eur Urol; 2015 Mar; 67(3):519-30. PubMed ID: 25449206
[TBL] [Abstract][Full Text] [Related]
33. Local treatments for metastases of renal cell carcinoma: a systematic review.
Dabestani S; Marconi L; Hofmann F; Stewart F; Lam TB; Canfield SE; Staehler M; Powles T; Ljungberg B; Bex A
Lancet Oncol; 2014 Nov; 15(12):e549-61. PubMed ID: 25439697
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O; Inanc M; Hacibekıroglu I; Esbah O; Seker M; Ulas A; Aydin K; Uysal M; Kücüköner M; Uncu D; Cıltas A; Unal OÜ; Durnali A; Demırcı U; Berk V; Tonyali O; Oksüzoglu B; Karaca H; Ozkan M
Anticancer Res; 2014 Aug; 34(8):4463-70. PubMed ID: 25075086
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
36. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
37. Prognostic variables and nomograms for renal cell carcinoma.
Flanigan RC; Polcari AJ; Hugen CM
Int J Urol; 2011 Jan; 18(1):20-31. PubMed ID: 21077960
[TBL] [Abstract][Full Text] [Related]
38. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Sternberg CN; Davis ID; Mardiak J; Szczylik C; Lee E; Wagstaff J; Barrios CH; Salman P; Gladkov OA; Kavina A; Zarbá JJ; Chen M; McCann L; Pandite L; Roychowdhury DF; Hawkins RE
J Clin Oncol; 2010 Feb; 28(6):1061-8. PubMed ID: 20100962
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK
J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
